Evaluation of the usefullness of perioperative administration of tiotropium and indacaterol in lung cancer patients with COPD

INTERVENTION: 18 microgram once daily Tiotropium 150 microgram once daily Indacaterol+ 18 microgram once daily Tiotropium CONDITION: Chronic obstructive pulmonary disease PRIMARY OUTCOME: forced expiratory volume in 1 second INCLUSION CRITERIA: 1) Non‐small cell lung cancer stage1 3. 2) Partial lung resection or lobectomy. 3) Patients with the clinical diagnosis of COPD and with a FEV1/FVC of < 70% after inhalation of beta 2 agonist. 4) Patients with GOLD stage 1 3. 5) Patients aged >40 years old. 6) Patients that provided consent/permission